Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
|
17013881 |
2007 |
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
|
17013881 |
2007 |
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
In a xenograft tumor model in which TGF-β was previously shown to elicit tumor-promoting effects, PDZK1IP1 gain of function decreased tumor size and increased survival rates.
|
30718277 |
2019 |
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Fascin-1 and MAP17 are stem cell markers whose excessive expression in tumors is associated with aggressive tumor phenotypes.
|
31273628 |
2019 |
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
We show that MAP17 expression is induced during lung tumourigenesis, particularly in lung adenocarcinomas, and provide in vitro and in vivo evidence that MAP17 levels predict sensitivity to therapies currently under clinical use in adenocarcinoma tumours, including cisplatin, carboplatin and EGFR inhibitors.
|
30119639 |
2018 |
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Conversely, MAP17 downregulation in a tumor cell line constitutively expressing this gene led to Notch pathway inactivation and a marked reduction of stemness.
|
28153862 |
2017 |
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Therefore, the combination of high MAP17 and SGLT1 levels is a marker for good prognosis in patients with cervical tumors after cisplatin plus radiotherapy treatment.
|
23418532 |
2013 |
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
In addition, we show that aberrant promoter hypomethylation-associated overexpression of MAP17 might promote tumor growth in thyroid cancer.
|
23666970 |
2013 |
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
We have found that MAP17 is expressed in 60% human mammary tumors while it is not expressed in normal or benign neoplasias.
|
22266858 |
2012 |
Neoplasms
|
0.080 |
AlteredExpression
|
group |
BEFREE |
In addition, DD96 is overexpressed markedly in various human carcinomas originating from the colon, breast, and lung, as well as in a number of cell lines derived from tumors of these organs compared with normal epithelial cell populations.
|
9815914 |
1995 |
Carcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
MAP17 (PDZK1IP1) is a small, 17 kDa non-glycosylated membrane protein located in the plasma membrane and Golgi apparatus and is overexpressed in a wide variety of human carcinomas.
|
30250642 |
2018 |
Carcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
MAP17 is a small nonglycosylated membrane protein that is overexpressed in a high percentage of carcinomas.
|
25837675 |
2015 |
Carcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
MAP17 is a small, 17-kDa, non-glycosylated membrane protein that is overexpressed in a percentage of carcinomas.
|
22266858 |
2012 |
Carcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
We identified MAP17, a small 17 kDa non-glycosylated membrane protein previously identified by differential display being over-expressed in carcinomas.
|
17548903 |
2007 |
Carcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Taken together, our data show an independent activation of MAP17 promoter that can be driven by oncogenes and that might explain the common overexpression of MAP17 in human carcinomas.
|
17426052 |
2007 |
Carcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Using in situ hybridization, we demonstrated that MAP17 and PDZK1 mRNAs are markedly up-regulated in human carcinomas.
|
10496535 |
1999 |
Carcinoma
|
0.070 |
AlteredExpression
|
group |
BEFREE |
In addition, DD96 is overexpressed markedly in various human carcinomas originating from the colon, breast, and lung, as well as in a number of cell lines derived from tumors of these organs compared with normal epithelial cell populations.
|
9815914 |
1995 |
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
MAP17 is aberrantly overexpressed in a number of malignancies.
|
29616128 |
2018 |
Tumor Progression
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, MAP17 is correlated with tumour progression.
|
30119639 |
2018 |
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties.
|
29616128 |
2018 |
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB.
|
28153862 |
2017 |
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB.
|
28153862 |
2017 |
Tumor Progression
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
p38α limits the contribution of MAP17 to cancer progression in breast tumors.
|
22266858 |
2012 |
Tumor Progression
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Immunohistochemical analysis of MAP17 during cancer progression shows, at least in prostate and ovarian carcinomas, that overexpression of the protein strongly correlates with tumoral progression (P < 0.0001).
|
17426052 |
2007 |
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Therefore, the protein cluster formed by the association of cMOAT, PDZK1, and MAP17 could play an important role in the cellular mechanisms associated with multidrug resistance, and PDZK1 may represent a new target in cancer cells resistant to chemotherapeutic agents.
|
10496535 |
1999 |